Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Early ivermectin does not prevent progression to severe COVID-19
The early addition of ivermectin to standard of care (SoC)* in high-risk patients with mild-to-moderate COVID-19 did not prevent progression to severe disease compared with SoC alone, according to results of the I-TECH** trial conducted in Malaysia.
Early ivermectin does not prevent progression to severe COVID-19
28 Feb 2022
Hepatitis C reinfection rates up in direct-acting antiviral era
There is an increased rate of hepatitis C virus (HCV) reinfection among people who inject drugs after the scale-up of direct-acting antivirals, reports a recent Scotland study.
Hepatitis C reinfection rates up in direct-acting antiviral era
26 Feb 2022
Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial
Use of famotidine in the treatment of outpatients with mild-to-moderate COVID-19 is safe and well tolerated, leading to rapid resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity, according to the results of a phase II trial.
Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial
25 Feb 2022
Dysglycaemia may increase likelihood of deterioration in non-severe COVID-19 patients
Patients with non-severe coronavirus disease 2019 (COVID-19) who have worse glycaemic status are more likely to deteriorate clinically, but glycaemic status does not adversely impact neutralizing antibody (NAb) responses, researchers from the University of Hong Kong have shown.
Dysglycaemia may increase likelihood of deterioration in non-severe COVID-19 patients
24 Feb 2022
Booster dose effective in reducing COVID-19 across ages in adults
The risk of COVID-19 is substantially reduced in adults who receive a third “booster” dose of the BNT162b2 vaccine regardless of their age, according to a study from Israel.
Booster dose effective in reducing COVID-19 across ages in adults
23 Feb 2022
Intranasal influenza-based booster induces mucosal immunity against SARS-CoV-2 in animal model
Research from the University of Hong Kong (HKU) demonstrates that intranasal influenza-based booster vaccination following PD1-based receptor-binding domain (RBD) DNA vaccine induces mucosal and systemic immunity for effective prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in both upper and lower respiratory systems of mice.
Intranasal influenza-based booster induces mucosal immunity against SARS-CoV-2 in animal model
23 Feb 2022
Self-reported adverse reactions less likely after inactivated CZ02 vs mRNA-based BNT162b2
A prospective cohort study by the University of Hong Kong comparing the reactogenicity of coronavirus disease 2019 (COVID-19) vaccines reports a lower risk of self-reported adverse reactions following vaccination with inactivated CZ02 compared with mRNA-based BNT162b2.
Self-reported adverse reactions less likely after inactivated CZ02 vs mRNA-based BNT162b2
23 Feb 2022
Knowing someone with COVID-19 a key predictor of vaccine uptake among HK adolescents
An online survey of over 2,500 Hong Kong adolescents has identified knowing someone diagnosed with coronavirus disease 2019 (COVID-19), having at least one vaccinated parent, and receiving the influenza vaccine in the past year as three top predictors of COVID-19 vaccine acceptance.